Is it possible to halve the incidence of liver cancer in China by 2050?
Related Experiment Video
Updated: Dec 7, 2025

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
Ju-Fang Shi1, Maomao Cao1, Yuting Wang2
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract:
A substantial proportion of liver cancers is attributable to chronic infection with hepatitis B and C (HBV/HCV). Liver cancer could become the second cancer, after cervical, to be effectively controlled globally, if proven interventions such as vaccination can be implemented on a large scale. In 2018, the global mortality rate for liver cancer was estimated to be 8.5 per 100 000 individuals. Given patterns of HBV infection and immigration across countries, liver cancer control requires combined, global action. Liver cancer trends vary between countries, in some Western countries, the incidence rates were relatively low but have increased in recent decades; conversely, in several Asian countries, the incidence rates have decreased over time. China has in the past contributed more than half of the global burden of liver cancer but more recently a national decline in liver cancer incidence has been observed. Here, we review the liver cancer burden and exposure to risk factors in China, compared to other countries. We also review the implementation status for primary and secondary prevention interventions and major outcomes achieved over the past three decades. Using Bayesian age-period-cohort analysis, we examine recent trends and based on these, predict that by 2050, the incidence of liver cancer in China could fall by half. We additionally survey the literature to identify current research needs, and review relevant national policies on liver cancer control in China. A comprehensive set of interventions is proposed to progress toward the long-term goal of liver cancer elimination based on the natural history and evidence-based interventions.
Insights
Liver cancer, often caused by hepatitis B and C (HBV/HCV) infections, is declining in China. With scaled-up vaccination and prevention, global liver cancer control is achievable.
Area of Science:
- Hepatology
- Oncology
- Public Health
Background:
- Chronic hepatitis B and C (HBV/HCV) infections are major causes of liver cancer globally.
- Liver cancer control is a significant global health challenge, with varying incidence rates across countries.
- China's historical contribution to the global liver cancer burden is substantial, though recent declines are observed.
Purpose of the Study:
- To review the liver cancer burden and risk factors in China compared to other nations.
- To assess the implementation and outcomes of liver cancer prevention interventions over three decades.
- To predict future liver cancer incidence trends in China and identify research needs and policy recommendations.
Main Methods:
- Bayesian age-period-cohort analysis to examine recent liver cancer trends in China.
- Literature survey to identify current research gaps and relevant national policies.
- Review of primary and secondary prevention intervention implementation and outcomes.
Main Results:
- Liver cancer incidence in China has shown a recent national decline.
- Projections indicate a potential halving of liver cancer incidence in China by 2050.
- Significant progress in implementing prevention interventions has been achieved over the past 30 years.
Conclusions:
- Global liver cancer control is feasible with widespread vaccination and scaled-up interventions.
- Targeted strategies and policies are crucial for achieving long-term liver cancer elimination.
- Continued research and policy refinement are necessary to address remaining challenges in liver cancer control.

